Plain-English translation of NCT05029336 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing autologous hematopoietic stem cell transplant (ASCT) — a procedure where doctors collect your own stem cells, give you high-dose immune-suppressing therapy to clear out the faulty immune cells causing your disease, and then return your stem cells to help your immune system rebuild. The goal is to 'reset' your immune system so it stops attacking your body. This approach has shown promise in adults with severe autoimmune diseases like lupus and systemic sclerosis (scleroderma) that don't respond well to standard treatments.
Some children and young adults have lupus or scleroderma that is so severe and aggressive that standard medicines don't work well enough — and these diseases can be life-threatening. This trial exists because doctors believe that a complete immune system reset using this treatment might give these young patients a real chance at remission or major improvement.
You likely qualify if…
You likely don't qualify if…
You would undergo high-dose immunosuppressive therapy, then receive an infusion of your own stem cells that have been specially processed to remove problematic immune cells. This is an intensive treatment requiring hospitalization and close medical monitoring during recovery. The trial will track your health and disease symptoms over time to see whether your immune system successfully resets and your disease improves. Your research team will explain the full timeline and what to expect at each stage.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States